Received May 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
ophthalmic complaints; neuritis; This Spontaneous report was received from Physician via a company representative, and referred to a 14 -year-old Female patient. The patient's concurrent condition included fever from an "unknown origin" and was being followed by Pediatric Infectious Disease prior to receiving the Vaccine. The patient's past medications and concomitant medications were not reported. On 09-May-2024, the patient received a single dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) (Route, anatomical site, lot# and expiration date were not reported) as Prophylaxis. In approximately 2024, the patient experienced ophthalmic complaints (Eye disorder) and neuritis (Neuritis) for which she sought medical attention in July 2024. At the reporting time, the patient had not received additional doses of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) and she had been followed by a Nephrologist. The Outcome of the events and the causal relationship with human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) was not provided. Lot number is being requested and will be submitted if received.
Fever of unknown origin